AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34264316 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab (3 mg/kg every 2 weeks + 1 mg/kg every 6 weeks)
Number of subjects: 252
Study 34264316 — intervention group
Group type: COMPARATOR
Intervention: Nivolumab alone (3 mg/kg every 2 weeks)
Number of subjects: 252
Study 34264316 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 252
Study 34264316 — intervention group
Group type: COMPARATOR
Intervention: Nivolumab alone
Number of subjects: 252
Study 33217031 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine group (group L, n = 40) received 1‐mg midazolam, 1.5 mg/kg lidocaine, and 1 mg/kg propofol intravenously
Number of subjects: 80
Study 33217031 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C, n = 40) received 1‐mg midazolam, saline in the same volume as the lidocaine group, and 1 mg/kg propofol intravenously
Number of subjects: 80
Study 33217031 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine group (group L)
Number of subjects: 80
Study 33217031 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 80
Study 32628922 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluocinolone acetonide implant (0.59 mg)
Number of subjects: 232
Study 32628922 — intervention group
Group type: COMPARATOR
Intervention: Systemic therapy (corticosteroid plus immunosuppression)
Number of subjects: 232
Study 33913373 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiamin 90 mg/day combined with folic acid 30 mg/day
Number of subjects: 50
Study 33913373 — intervention group
Group type: COMPARATOR
Intervention: Nonintervention (Control)
Number of subjects: 50
Study 32555047 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (NSAID)
Number of subjects: 102
Study 32555047 — intervention group
Group type: COMPARATOR
Intervention: Control (Acetaminophen)
Number of subjects: 102
Study 35673085 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention snippets from 261 randomized clinical trial (RCT) abstracts
Number of subjects: 0
Study 34486352 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 kg ha⁻¹ phosphorus and 8.0 t ha⁻¹ lime
Number of subjects: 16
Study 36228734 — intervention group
Group type: EXPERIMENTAL
Intervention: Vonoprazan, 20 mg
Number of subjects: 1024
Study 36228734 — intervention group
Group type: EXPERIMENTAL
Intervention: Vonoprazan, 10 mg
Number of subjects: 1024
Study 36228734 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole, 30 mg
Number of subjects: 1024
Study 33905836 — intervention group
Group type: EXPERIMENTAL
Intervention: Strabismus surgery
Number of subjects: 197
Study 32227638 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous thrombolysis (alteplase)
Number of subjects: 431
Study 32227638 — intervention group
Group type: EXPERIMENTAL
Intervention: DWI-FLAIR mismatch
Number of subjects: 431
Study 32227638 — intervention group
Group type: EXPERIMENTAL
Intervention: PWI-DWI mismatch
Number of subjects: 431
Study 32227638 — intervention group
Group type: EXPERIMENTAL
Intervention: Mismatch screening
Number of subjects: 431
Study 32227638 — intervention group
Group type: EXPERIMENTAL
Intervention: PWI-DWI mismatch status
Number of subjects: 431
Study 35760566 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance care planning (ACP) intervention; patients received an oncologist letter supporting them to request a GP review along with a patient information leaflet about ACP.
Number of subjects: 46
Study 35760566 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group).
Number of subjects: 46
Study 35760566 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life measures (EuroQol EQ-5D-5L and ICECAP Supportive Care Measure) at baseline, 6, 12, 24, and 48 weeks.
Number of subjects: 46
Study 35760566 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative interviews exploring patient, carer, and GP experiences.
Number of subjects: 46
Study 35760566 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological or clinical harms assessment.
Number of subjects: 46
Study 33667726 — intervention group
Group type: EXPERIMENTAL
Intervention: KHK inhibitor PF‐06835919
Number of subjects: 2
Study 33667726 — intervention group
Group type: COMPARATOR
Intervention: Single oral doses of PF‐06835919
Number of subjects: 2
Study 35803627 — intervention group
Group type: EXPERIMENTAL
Intervention: Online self-management fall prevention intervention (group-based, six 2-hour weekly sessions, plus a booster session 8 weeks later)
Number of subjects: 48
Study 35803627 — intervention group
Group type: COMPARATOR
Intervention: Control group (received a brochure about fall risk factors and fall prevention)
Number of subjects: 48
Study 33373553 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth sessions
Number of subjects: 200
Study 36429821 — intervention group
Group type: EXPERIMENTAL
Intervention: Network psychometrics methodology
Number of subjects: 367
Study 36429821 — intervention group
Group type: EXPERIMENTAL
Intervention: Network centrality measures (eigencentrality, strength, bridge centrality)
Number of subjects: 367
Study 33565359 — intervention group
Group type: EXPERIMENTAL
Intervention: Uroflowmetry (Group A)
Number of subjects: 50
Study 33565359 — intervention group
Group type: COMPARATOR
Intervention: Urodynamic study (Group B)
Number of subjects: 50
Study 36056176 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss-framing of information on vaccine effectiveness
Number of subjects: 298
Study 36056176 — intervention group
Group type: EXPERIMENTAL
Intervention: BioNTech brand, higher efficacy, less serious adverse events, more vaccination coverage in children
Number of subjects: 298
Study 36056176 — intervention group
Group type: EXPERIMENTAL
Intervention: Presentation of mortality information
Number of subjects: 298
Study 36056176 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental uptake of the COVID-19 vaccine
Number of subjects: 298
Study 36056176 — intervention group
Group type: EXPERIMENTAL
Intervention: Children's age
Number of subjects: 298
Study 34793646 — intervention group
Group type: EXPERIMENTAL
Intervention: RFT through foramen rotundum (RFT-FR)
Number of subjects: 70
Study 34793646 — intervention group
Group type: EXPERIMENTAL
Intervention: RFT through foramen ovale (RFT-FO)
Number of subjects: 70
Study 34793646 — intervention group
Group type: EXPERIMENTAL
Intervention: RFT-FR
Number of subjects: 70
Study 34793646 — intervention group
Group type: EXPERIMENTAL
Intervention: RFT-FO
Number of subjects: 70
Study 36216768 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary cotinine (UCot) measurements categorized into three groups
Number of subjects: 980
Study 36216768 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated breast RT
Number of subjects: 980
Study 36216768 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking (as indicated by UCot)
Number of subjects: 980
Study 36216768 — intervention group
Group type: EXPERIMENTAL
Intervention: Light smoker/secondhand smoke exposure (as indicated by UCot)
Number of subjects: 980
Study 36216768 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (acute RISI)
Number of subjects: 980
Study 34143241 — intervention group
Group type: EXPERIMENTAL
Intervention: Consecutive practice (INT consecutive)
Number of subjects: 45
Study 34143241 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent practice (INT concurrent)
Number of subjects: 45
Study 34143241 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 45
Study 32040044 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoclonal anti‐Aβ antibodies (bapineuzumab, solanezumab, gantenerumab, crenezumab, aducanumab)
Number of subjects: 0
Study 35196381 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT) telephone-delivered coaching
Number of subjects: 1170
Study 35196381 — intervention group
Group type: COMPARATOR
Intervention: Standard quitline (QL) telephone-delivered coaching
Number of subjects: 1170
Study 34325886 — intervention group
Group type: EXPERIMENTAL
Intervention: MitraClip plus guideline-directed medical therapy (GDMT)
Number of subjects: 614
Study 34325886 — intervention group
Group type: COMPARATOR
Intervention: Guideline-directed medical therapy (GDMT) alone
Number of subjects: 614
Study 32336045 — intervention group
Group type: EXPERIMENTAL
Intervention: GDNF-DNMG-modified DNM-S (DNM-S/GDNF@DNMG)
Number of subjects: 15
Study 32336045 — intervention group
Group type: COMPARATOR
Intervention: DNM-S
Number of subjects: 15
Study 32336045 — intervention group
Group type: COMPARATOR
Intervention: Autograft
Number of subjects: 15
Study 35181219 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Number of subjects: 80
Study 35181219 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 80
Study 33640581 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically determined copper levels
Number of subjects: 0
Study 33640581 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically determined zinc levels
Number of subjects: 0
Study 33640581 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically determined calcium levels
Number of subjects: 0
Study 35513775 — intervention group
Group type: EXPERIMENTAL
Intervention: Partners with secondary or higher education
Number of subjects: 519
Study 35513775 — intervention group
Group type: COMPARATOR
Intervention: Partners with less than secondary education
Number of subjects: 519
Study 35513775 — intervention group
Group type: EXPERIMENTAL
Intervention: Partners’ education level
Number of subjects: 519
Study 33399411 — intervention group
Group type: EXPERIMENTAL
Intervention: Anal inserts
Number of subjects: 50
Study 33399411 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous tibial nerve stimulation
Number of subjects: 50
Study 33399411 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 50
Study 32536587 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-cured self-adhesive cement without pretreatment (Group I)
Number of subjects: 0
Study 32536587 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-cured self-adhesive cement after polyacrylic acid treatment (Group II)
Number of subjects: 0
Study 32536587 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-cured self-adhesive cement with universal dentin adhesive pre-cure method (Group III)
Number of subjects: 0
Study 32536587 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-cured self-adhesive cement with universal dentin adhesive co-cure method (Group IV)
Number of subjects: 0
Study 32536587 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-cure mode cementation (Group V)
Number of subjects: 0
Study 32536587 — intervention group
Group type: COMPARATOR
Intervention: Panavia V5 (Kuraray Noritake) - Control group
Number of subjects: 0
Study 36016763 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg caffeine (CAF)
Number of subjects: 48
Study 36016763 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 150 mg caffeine, 100 mg methylliberine, and 50 mg theacrine (CMT)
Number of subjects: 48
Study 36016763 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 48
Study 32692990 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine (LB) infiltration of the BMG harvest site
Number of subjects: 43
Study 32692990 — intervention group
Group type: COMPARATOR
Intervention: No further local anesthetic infiltration (Control)
Number of subjects: 43
Study 35550457 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA), 24 sessions
Number of subjects: 60
Study 35550457 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture, 24 sessions
Number of subjects: 60
Study 35550457 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 60
Study 32516839 — intervention group
Group type: COMPARATOR
Intervention: COVID-19 convalescent plasma (CCP) therapy, 200-400 ml of plasma collected from donors with antibody titres > 1:160.
Number of subjects: 700
Study 35037816 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenzilumab plus standard of care (SOC)
Number of subjects: 0
Study 35037816 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC) alone
Number of subjects: 0
Study 35037816 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenzilumab plus SOC
Number of subjects: 0
Study 34006540 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated community-based (ICB) care
Number of subjects: 900
Study 34006540 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 900
Study 32959583 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic scalp acupuncture combined with task-oriented mirror therapy (TOMT)
Number of subjects: 78
Study 32959583 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalp acupuncture combined with TOMT
Number of subjects: 78
Study 32959583 — intervention group
Group type: COMPARATOR
Intervention: Task-oriented mirror therapy (TOMT)
Number of subjects: 78
Study 35209951 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure targets of 63 mmHg
Number of subjects: 0
Study 35209951 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure targets of 77 mmHg
Number of subjects: 0
Study 35209951 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive oxygen concentration (9–10 kPa) during mechanical ventilation
Number of subjects: 0
Study 35209951 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal oxygen concentration (13–14 kPa) during mechanical ventilation
Number of subjects: 0
Study 35209951 — intervention group
Group type: EXPERIMENTAL
Intervention: Device-based active fever management discontinued after 36 h or 72 h
Number of subjects: 0
Study 35209951 — intervention group
Group type: COMPARATOR
Intervention: Standard of care including targeted temperature management at 36 °C for 24 h
Number of subjects: 0
Study 35209951 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to initiation of renal replacement therapy or death
Number of subjects: 0
Study 35209951 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuron-specific enolase (NSE) level at 48 h
Number of subjects: 0
Study 35209951 — intervention group
Group type: EXPERIMENTAL
Intervention: MOCA score at day 90
Number of subjects: 0
Study 35209951 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Ranking Scale (mRS) and CPC at 3 months
Number of subjects: 0
Study 35209951 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-pro-BNP at 90 days
Number of subjects: 0
Study 35209951 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR and LVEF at 90 days
Number of subjects: 0
Study 35209951 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily cumulated vasopressor requirement during ICU stay
Number of subjects: 0
Study 35209951 — intervention group
Group type: EXPERIMENTAL
Intervention: Need for a combination of vasopressors and inotropic agents or mechanical circulatory support
Number of subjects: 0
Study 33496396 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care (POC) pathway
Number of subjects: 124
Study 33496396 — intervention group
Group type: COMPARATOR
Intervention: Standard pathway
Number of subjects: 124
Study 33496396 — intervention group
Group type: EXPERIMENTAL
Intervention: POC pathway
Number of subjects: 124
Study 36273185 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening and intervention (includes parent-report child anxiety screening questionnaire, feedback on screening outcomes, lesson on managing fears and worries, and OSI offered to parents of children who screen positive)
Number of subjects: 398
Study 36273185 — intervention group
Group type: COMPARATOR
Intervention: Usual school practice (assessment and usual school practice only)
Number of subjects: 398
Study 33844258 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic uterine bracket set at 260 mmHg (Group B)
Number of subjects: 148
Study 33844258 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic uterine bracket set at 280 mmHg (Group C)
Number of subjects: 148
Study 33844258 — intervention group
Group type: COMPARATOR
Intervention: Control group with pneumatic uterine bracket set at 240 mmHg (Group A)
Number of subjects: 148
Study 33844258 — intervention group
Group type: COMPARATOR
Intervention: Pneumatic uterine bracket set at 240 mmHg (Group A)
Number of subjects: 148
Study 33522636 — intervention group
Group type: EXPERIMENTAL
Intervention: Preceptors' education intervention (face-to-face education about orientation)
Number of subjects: 72
Study 33522636 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 72
Study 32139505 — intervention group
Group type: EXPERIMENTAL
Intervention: Golodirsen (30 mg/kg)
Number of subjects: 25
Study 32139505 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 35744082 — intervention group
Group type: EXPERIMENTAL
Intervention: Decellularized bovine peritoneum (DBP)
Number of subjects: 68
Study 35744082 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 68
Study 33639181 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV vaccination (three doses of Cervarix®)
Number of subjects: 6226
Study 33639181 — intervention group
Group type: COMPARATOR
Intervention: Non-HPV vaccination (reference cohort)
Number of subjects: 6226
Study 32651047 — intervention group
Group type: EXPERIMENTAL
Intervention: Section 8 rental voucher (treatment group)
Number of subjects: 750
Study 32651047 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer drug use (mediator)
Number of subjects: 750
Study 32651047 — intervention group
Group type: COMPARATOR
Intervention: Public housing (control group)
Number of subjects: 750
Study 36278480 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioural therapy (ICBT) combined with attentional bias modification training (ABM)
Number of subjects: 63
Study 36278480 — intervention group
Group type: COMPARATOR
Intervention: Internet-based cognitive behavioural therapy (ICBT) combined with ABM placebo
Number of subjects: 63
Study 32909439 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular hyaluronic acid (HA) injections
Number of subjects: 187
Study 35797024 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline nasal irrigation (SNI) with 400 mg theophylline
Number of subjects: 51
Study 35797024 — intervention group
Group type: COMPARATOR
Intervention: Saline nasal irrigation (SNI) with placebo (500 mg lactose powder)
Number of subjects: 51
Study 33825587 — intervention group
Group type: EXPERIMENTAL
Intervention: Baduanjin Qigong (8 weeks, 3 sessions per week followed by home-based practice 3 days a week for another 8 weeks)
Number of subjects: 58
Study 33825587 — intervention group
Group type: COMPARATOR
Intervention: Conventional fitness training (2 sessions in the first week followed by home-based exercise practice 3 days a week until week 16)
Number of subjects: 58
Study 97175823 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative ERC with ESE followed by LC during the same hospital admission (Group A)
Number of subjects: 207
Study 97175823 — intervention group
Group type: COMPARATOR
Intervention: Single stage laparoscopic management consisting of LC and laparoscopic stone extraction (Group B)
Number of subjects: 207
Study 35243022 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Radiotherapy (SABR) in combination with ongoing systemic therapy
Number of subjects: 68
Study 35243022 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (switch to the next line of treatment, continue same treatment or observation)
Number of subjects: 68
Study 33409726 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led telephone follow-up
Number of subjects: 183
Study 33409726 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 183
Study 36421329 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine e‐cigarette plus support
Number of subjects: 210
Study 36421329 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine-free e‐cigarette plus support
Number of subjects: 210
Study 36421329 — intervention group
Group type: COMPARATOR
Intervention: Support
Number of subjects: 210
Study 34159208 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall PRP group (intraoperative PRP augmentation)
Number of subjects: 58
Study 34159208 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PRP treatment)
Number of subjects: 58
Study 34159208 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall PRP group
Number of subjects: 58
Study 34159208 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP-booster group
Number of subjects: 58
Study 34159208 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP-only group
Number of subjects: 58
Study 36201709 — intervention group
Group type: EXPERIMENTAL
Intervention: Improving shared decision making (SDM)
Number of subjects: 173
Study 33612080 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to vigorous physical activity (MVPA)
Number of subjects: 186
Study 32729615 — intervention group
Group type: EXPERIMENTAL
Intervention: early time-restricted feeding (eTRF)
Number of subjects: 16
Study 35060543 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung-conduction exercises (LCE), medication + LCE, 5 times a week, n = 8
Number of subjects: 25
Study 35060543 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation (PR), medication + PR, 5 times a week, n = 8
Number of subjects: 25
Study 35060543 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC), only medication, n = 9
Number of subjects: 25
Study 33846054 — intervention group
Group type: EXPERIMENTAL
Intervention: C-R/R using autodialer in Colorado
Number of subjects: 224
Study 33846054 — intervention group
Group type: EXPERIMENTAL
Intervention: C-R/R using mail in Colorado
Number of subjects: 224
Study 33846054 — intervention group
Group type: EXPERIMENTAL
Intervention: C-R/R using autodialer in New York
Number of subjects: 224
Study 33846054 — intervention group
Group type: EXPERIMENTAL
Intervention: C-R/R using text in New York
Number of subjects: 224
Study 33846054 — intervention group
Group type: COMPARATOR
Intervention: Control group in Colorado
Number of subjects: 224
Study 33846054 — intervention group
Group type: COMPARATOR
Intervention: Control group in New York
Number of subjects: 224
Study 33846054 — intervention group
Group type: EXPERIMENTAL
Intervention: C-R/R overall
Number of subjects: 224
Study 33846054 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost per adolescent for mail
Number of subjects: 224
Study 34473334 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcuminoids (exact dosage and duration not specified)
Number of subjects: 0
Study 34473334 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0